These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway. Liu X, Xiao XY, Shou QY, Yan JF, Chen L, Fu HY, Wang JC. J Ethnopharmacol; 2016 Dec 04; 193():538-545. PubMed ID: 27686271 [Abstract] [Full Text] [Related]
31. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R. Cancer Chemother Pharmacol; 2007 Apr 04; 59(5):589-601. PubMed ID: 16924497 [Abstract] [Full Text] [Related]
35. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Qin JJ, Wang W, Voruganti S, Wang H, Zhang WD, Zhang R. Oncotarget; 2015 Feb 20; 6(5):2623-40. PubMed ID: 25739118 [Abstract] [Full Text] [Related]
37. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Chen H, Sun B, Pan S, Jiang H, Sun X. Anticancer Drugs; 2009 Feb 20; 20(2):131-40. PubMed ID: 19209030 [Abstract] [Full Text] [Related]
40. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression. Fu XH, Zhang X, Yang H, Xu XW, Hu ZL, Yan J, Zheng XL, Wei RR, Zhang ZQ, Tang SR, Geng MY, Huang X. Acta Pharmacol Sin; 2019 May 20; 40(5):677-688. PubMed ID: 30224636 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]